AbbVie (ABBV) 7th Annual Healthcare Symposium summary
Event summary combining transcript, slides, and related documents.
7th Annual Healthcare Symposium summary
9 Jul, 2026Key trends in vaccine confidence and hesitancy
Vaccine hesitancy has doubled among parents in the past five years, but most still support routine childhood immunization.
Trust in institutions has declined, but healthcare professionals, especially pediatricians, remain highly trusted sources.
Social media can amplify both misinformation and trusted local voices, with pediatricians on platforms like TikTok playing a positive role.
Broader societal and political divides, not just misinformation, now drive hesitancy.
Fear, uncertainty, and the success of vaccines (making diseases less visible) contribute to lower perceived need.
Strategies for improving access and equity
Pediatric vaccine access in the U.S. is strong due to commercial coverage and the Vaccines for Children Program, covering about half of American children.
Barriers to access are more often related to information and healthcare logistics than cost.
Globally, creative solutions like Gavi, COVAX, and pooled purchasing help balance innovation incentives with affordability.
Regionalizing vaccine manufacturing and improving surveillance can enhance equity and rapid response.
Communication, value, and trust-building
Value and access teams focus on demonstrating holistic vaccine value, including societal and economic benefits, to payers and policymakers.
Trusted messengers, such as local pharmacists and community leaders, are key to effective communication.
Empowering providers with education and tools enhances their ability to translate policy into practice.
Latest events from AbbVie
- Strong financials, pipeline growth, and governance reform efforts marked the annual meeting.ABBV
AGM 20259 Jul 2026 - Strong pipeline and innovative R&D strategies support sustained growth and market leadership.ABBV
TD Cowen 46th Annual Health Care Conference8 Jul 2026 - Strong growth outlook driven by innovation in immunology, neuroscience, and oncology.ABBV
Goldman Sachs 45th Annual Global Healthcare Conference8 Jul 2026 - Strong growth in immunology and neuroscience, with robust pipeline and strategic expansion ahead.ABBV
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Q3 revenue up 3.8%, Skyrizi and Rinvoq growth offset Humira declines; guidance and dividend raised.ABBV
Q3 20248 Jul 2026 - $10.9B acquisition adds late-stage immunology assets, targeting blockbuster growth by 2032.ABBV
M&A announcement22 Jun 2026 - Four growth pillars and strong pipeline drive robust outlook and long-term expansion.ABBV
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Strong growth, margin expansion, and pipeline innovation highlighted across core and emerging areas.ABBV
Bank of America Global Healthcare Conference 202619 May 2026 - Q1 2026 revenue up 12.4% to $15B, with strong EPS, raised guidance, and major U.S. investments.ABBV
Q1 20268 May 2026